Ragland DA, Nalivaika EA, Nalam MN, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA. "Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease." (2014) Found on Publication Page
Ragland DA, Nalivaika EA, Nalam MN, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA. "Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease." (2014)
Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA. "Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50." (2013) Found on Publication Page
Mittal S, Bandaranayake RM, King NM, Prabu-Jeyabalan M, Nalam MN, Nalivaika EA, Yilmaz NK, Schiffer CA. "Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50." (2013)
King NM, Prabu-Jeyabalan M, Bandaranayake RM, Nalam MN, Nalivaika EA, Ozen A, Haliloglu T, Yilmaz NK, Schiffer CA. "Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease." (2012) Found on Publication Page
King NM, Prabu-Jeyabalan M, Bandaranayake RM, Nalam MN, Nalivaika EA, Ozen A, Haliloglu T, Yilmaz NK, Schiffer CA. "Extreme entropy-enthalpy compensation in a drug-resistant variant of HIV-1 protease." (2012)
Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. "Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F." (2012) Found on Publication Page
Bandaranayake RM, Ungureanu D, Shan Y, Shaw DE, Silvennoinen O, Hubbard SR. "Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F." (2012)
Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MNL, Nalivaika EA, Ozen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA. "Molecular Basis for Drug Resistance in HIV-1 Protease." (2010) Found on Publication Page
Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, Murzycki JF, Nalam MNL, Nalivaika EA, Ozen A, Prabu-Jeyabalan MM, Thayer K, Schiffer CA. "Molecular Basis for Drug Resistance in HIV-1 Protease." (2010)
Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA. "The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways." (2010) Found on Publication Page
Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA. "The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways." (2010)
Bandaranayake RM, Prabu-Jeyabalan M, Kakizawa J, Sugiura W, Schiffer CA. "Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6." (2008) Found on Publication Page
Bandaranayake RM, Prabu-Jeyabalan M, Kakizawa J, Sugiura W, Schiffer CA. "Structural analysis of human immunodeficiency virus type 1 CRF01_AE protease in complex with the substrate p1-p6." (2008)
Felix AM, Bandaranayake RM. "Synthesis of bis- and tris-branched COOH-terminal pegylating reagents: conjugation to NH-terminal peptides." (2005) Found on Publication Page
Felix AM, Bandaranayake RM. "Synthesis of bis- and tris-branched COOH-terminal pegylating reagents: conjugation to NH-terminal peptides." (2005)
Felix AM, Bandaranayake RM. "Synthesis of symmetrically and asymmetrically branched pegylating reagents." (2004) Found on Publication Page
Felix AM, Bandaranayake RM. "Synthesis of symmetrically and asymmetrically branched pegylating reagents." (2004)
Minimum size is 350x300, maximum size is 800x800
Showcase your research interests